Roche/GSK Boniva Launch Will Await Less Frequent Dose Approval
Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen
Roche and GlaxoSmithKline will hold off launching the osteoporosis agent Boniva (ibandronate) until approval of a less frequent dosing regimen